Kidney Disease Treatment: Medical Management, Lifestyle, and Replacement Therapy

Chronic kidney disease (CKD) management is stage-based (KDIGO guidelines) and individualized.

1. Pharmacotherapy

  • RAAS inhibition: ACEi/ARB — first-line for proteinuric CKD (↓ intraglomerular pressure). Monitor K+, Cr.
  • SGLT2 inhibitors: Empagliflozin, dapagliflozin — renal + CV benefit even in non-diabetics (DAPA-CKD, EMPA-KIDNEY).
  • Blood pressure: Target <130/80 (KDIGO 2021). Often requires 2–3 agents.
  • Anemia: ESA (epoetin, darbepoetin) if Hb <10 g/dL + iron replete.
  • Mineral bone disease: Phosphate binders, vitamin D analogs, calcimimetics per KDIGO.
  • Acidosis: Sodium bicarbonate if HCO₃⁻ <22 mmol/L.

2. Diet & Lifestyle

  • Sodium: <2 g/day (5 g salt) — BP and volume control.
  • Protein: 0.8 g/kg/day (non-dialysis); avoid high animal protein.
  • Potassium: Restrict only if hyperkalemic (stage 4–5).
  • Plant-dominant diet: Mediterranean / DASH — slower progression.
  • Weight, exercise, smoking cessation, glycemic control.

3. Kidney Replacement Therapy (KRT) — Stage 5 (eGFR <15) or Uremic Symptoms

  • Hemodialysis: 3×/wk, 3–4 hr/session (in-center or home).
  • Peritoneal dialysis: Daily exchanges (CAPD) or cycler (APD) — home-based, preserves residual function.
  • Transplant: Living donor (best outcomes) or deceased donor. Pre-emptive (before dialysis) ideal.
  • Conservative management: Symptom-focused, no dialysis — for frail, elderly, multimorbid.

Multidisciplinary Team

Nephrologist, renal dietitian, social worker, pharmacist, vascular access coordinator, transplant coordinator, palliative care (early integration).

Early nephrology referral (stage 3b–4) improves preparation, access creation, and survival.

Kidney Disease - Related Articles